Transforming Cancer Care:
Introducing TVAX
Immunotherapy®
TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved clinical outcomes and low toxicity and the potential for fundamentally changing the way cancer is treated. Learn More
More About TVAX Immunotherapy®
Successes &
Breakthroughs
Discover TVAX Biomedical’s innovative strides in cancer treatment. Explore our pioneering research, clinical milestones, and regulatory recognitions shaping the future of cancer care. Join us in celebrating our transformative achievements and ongoing commitment to improving patient outcomes with TVAX Immunotherapy.
Scientific Breakthroughs:
Leveraging 50+ years of cancer research, TVAX Biomedical pioneers breakthroughs in immune system interaction, shaping TVAX Immunotherapy's development
Clinical Progress:
TVAX's rigorous clinical testing advances its immunotherapy platform from preclinical studies to Phase 2 trials, showcasing its safety, efficacy, and transformative potential in cancer care.
Regulatory Recognition:
Regulatory accolades from the FDA, including Fast Track and Orphan Product Designation, underscore TVAX Immunotherapy's innovative approach and promise in addressing unmet needs in cancer care
TVAX’s lead candidate (TVI-Brain-1) :
TVI-Brain-1 is currently being evaluated for the treatment of brain cancer, specifically glioblastoma. The company has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) to conduct a pivotal Phase 2b trial for TVI-Brain-1 to support the therapy’s potential FDA approval.
The TVAX® Platform:
Revolutionizing Cancer Treatment
At TVAX Biomedical, we’re spearheading a groundbreaking approach to cancer treatment with the TVAX® Platform. Here’s why it’s poised to transform the landscape of cancer care:
Pioneering a New Era in Cancer Treatment
TVAX Immunotherapy® combines personalized cancer cell vaccination and “killer” T cell treatment, leveraging over 50 years of scientific research into cancer-immune system interactions. This unique platform offers the promise of improved clinical outcomes, low toxicity, and the potential to fundamentally change cancer treatment.
Management Name
Management Name
Management Name
Meet Our Management Team.
The TVAX® management team consists of experienced executives with proven track records of success, who together possess the expertise required to conduct clinical studies as well as direct the related scientific and business operations. Additionally, the team possesses critical manufacturing expertise which will be essential in the scale-up required for ultimate commercialization of the TVAX platform.
Latest News & Articles
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
TVAX Biomedical Initiates Phase 2b Trial for TVI-Brain-1 in Glioblastoma Patients.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Read More
TVAX Biomedical Initiates Phase 2b Trial for TVI-Brain-1 in Glioblastoma Patients.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Read More
TVAX Biomedical Initiates Phase 2b Trial for TVI-Brain-1 in Glioblastoma Patients.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.